Carna Biosciences: Notice of decision to start BTK inhibitor AS-1763 phase 1b test dose expansion part
Carna Biosciences: Notice of patent assessment in Europe relating to a joint patent application with Gilead Sciences
Carna Biosciences: Report of transfer of new shares for third-party allotment.
Carna Biosciences: Announcements of individual stocks regarding patent assessment in China for BTK inhibitor AS-1763 pharmaceutical composition.
Carna Biosciences: Promising initial data from the phase 1b clinical trial of the next-generation BTK inhibitor AS-1763 targeting mature B-cell tumors will be presented at the European Hematology Association (EHA) in 2024.
Carna Biosciences: Stock transfer report agreement relating to third party allotment (new shares)
Carna Biosciences: Notice of presentation at European Society of Hematology (EHA) 2024 on BTK inhibitor AS-1763
Carna Biosciences: Outline of the poster presentation at the American Cancer Society (AACR) annual meeting on the CDC7 inhibitor monzosertib
Carna Biosciences: Notice of presentation at the American Cancer Society (AACR) annual meeting on the CDC7 inhibitor monzosertib
Carna Biosciences: End of license agreement with Fresh Trax Therapeutics
Carna Biosciences: Announcement of joint research paper with the Cancer Research Group
Carna Biosciences: Independent Officer Registration Form
Carna Biosciences: Notice regarding executive personnel
Carna Biosciences: Notice regarding the introduction of a post-issuance performance-linked stock reward system (performance share unit system)
Carna Biosciences: Matters relating to business plans and growth potential
Carna Biosciences: Announcement of development progress of next-generation profiling using Biophase 8800 in SLAS2024
Carna Biosciences: Announcement of joint research results with Carterra for SLAS2024
Carna Biosciences: Notice of patent assessment in the United States relating to the STING antagonist created by our company
Carna Biosciences: Notice of patent assessment in China relating to a joint patent application with Gilead Sciences
Carna Biosciences: Notice of receipt of Milestone Payments from Gilead
No Data
No Data